{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:44:54Z","timestamp":1793407494723,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T00:00:00Z","timestamp":1605657600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T00:00:00Z","timestamp":1605657600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["116020"],"award-info":[{"award-number":["116020"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Obtaining reliable estimates of the health-related quality of life (HR-QoL) of people with predementia Alzheimer\u2019s disease [AD] (preclinical or prodromal AD), mild cognitive impairment (MCI) and dementia is essential for economic evaluations of related health interventions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To provide an overview of which quality of life instruments are being used to assess HR-QoL in people with predementia AD, MCI or dementia; and, to summarise their reported HR-QoL levels at each stage of the disease and by type of respondent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched for and reviewed eligible studies published between January 1990 and the end of April 2017 which reported HR-QoL for people with predementia AD, MCI or dementia. We only included instruments which are preference-based, allowing index scores\/utility values to be attached to each health state they describe based on preferences obtained from population surveys. Summary results were presented by respondent type (self or proxy), type of instrument, geographical location and, where possible, stage of disease.<\/jats:p>\n                    <jats:p>Health state utility values derived using the EuroQoL 5-Dimensions (EQ-5D) were meta-analysed by pooling reported results across all studies by disease severity (MCI, mild, mild to moderate, moderate, severe dementia, not specified) and by respondent (person with dementia, carer, general public, not specified), using a fixed-effects approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 61 studies which reported HR-QoL for people with MCI or dementia using preference-based instruments, of which 48 used the EQ-5D. Thirty-six studies reported HR-QoL for mild and\/or moderate disease severities, and 12 studies reported utility values for MCI.<\/jats:p>\n                    <jats:p>We found systematic differences between self-rated and proxy-rated HR-QoL, with proxy-rated utility valued being significantly lower in more severe disease states.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A substantial literature now exists quantifying the impact of dementia on HR-QoL using preference-based measures, giving researchers and modellers a firmer basis on which to select appropriate utility values when estimating the effectiveness and cost-effectiveness of interventions in this area. Further research is required on HR-QoL of people with preclinical and prodromal AD and MCI, possible differences by type of dementia, the effects of comorbidities, study setting and the informal caregiver\u2019s own HR-QoL, including any effect of that on their proxy-ratings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-020-00723-1","type":"journal-article","created":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T11:04:33Z","timestamp":1605697473000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":88,"title":["Health-related quality of life in people with predementia Alzheimer\u2019s disease, mild cognitive impairment or dementia measured with preference-based instruments: a systematic literature review"],"prefix":"10.1186","volume":"12","author":[{"name":"on behalf of the ROADMAP consortium","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2842-2195","authenticated-orcid":false,"given":"Filipa","family":"Landeiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seher","family":"Mughal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsbeth","family":"Nye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine","family":"Morton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harriet","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Ghinai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yovanna","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Leal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nia","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Wace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Handels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Lecomte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Gustavsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilse","family":"Roncancio-Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Belger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurleen S.","family":"Jhuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacoline C.","family":"Bouvy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele H.","family":"Potashman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Tockhorn-Heidenreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alastair M.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,18]]},"reference":[{"key":"723_CR1","volume-title":"Dementia: assessment, management and support for people living with dementia and their carers","author":"National Institute for Health and Care Excellence","year":"2018","unstructured":"National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers. London: NICE; 2018. https:\/\/www.nice.org.uk\/guidance\/ng97. Accessed 14 Dec 2018."},{"key":"723_CR2","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/S1474-4422(08)70169-8","volume":"7","author":"RN Kalaria","year":"2008","unstructured":"Kalaria RN, Maestre GE, Arizaga R, Friedland RP, Galasko D, Hall K, et al. Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurol. 2008;7:812\u201326.","journal-title":"Lancet Neurol"},{"key":"723_CR3","doi-asserted-by":"publisher","first-page":"908915","DOI":"10.1155\/2014\/908915","volume":"2014","author":"L Rizzi","year":"2014","unstructured":"Rizzi L, Rosset I, Roriz-Cruz M. Global epidemiology of dementia: Alzheimer\u2019s and vascular types. Biomed Res Int. 2014;2014:908915.","journal-title":"Biomed Res Int"},{"key":"723_CR4","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1212\/WNL.54.1.4","volume":"54","author":"A Lobo","year":"2000","unstructured":"Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di Carlo A, Breteler MM, et al. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology. 2000;54:S4\u20139.","journal-title":"Neurology."},{"issue":"4","key":"723_CR5","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1590\/1980-57642016dn11-040005","volume":"11","author":"N Custodio","year":"2017","unstructured":"Custodio N, Montesinos R, Lira D, Herrera-Perez E, Bardales Y, Valeriano-Lorenzo L. Mixed dementia: a review of the evidence. Dement Neuropsychol. 2017;11(4):364\u201370.","journal-title":"Dement Neuropsychol"},{"key":"723_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0022-510X(02)00256-3","volume":"203-204","author":"R Kalaria","year":"2002","unstructured":"Kalaria R. Similarities between Alzheimer's disease and vascular dementia. J Neurol Sci. 2002;203-204:29\u201334.","journal-title":"J Neurol Sci"},{"issue":"22","key":"723_CR7","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1056\/NEJMoa0806142","volume":"360","author":"GM Savva","year":"2009","unstructured":"Savva GM, Wharton SG, Ince PG, Forster G, Matthews FE, Brayne C, et al. Age, neuropathology, and dementia. N Engl J Med. 2009;360(22):2302\u20139.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"723_CR8","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1186\/alzrt198","volume":"5","author":"H Chertkow","year":"2013","unstructured":"Chertkow H, Feldman HH, Jacova C, Massoud F. Definitions of dementia and predementia states in Alzheimer\u2019s disease and vascular cognitive impairment: consensus from the Canadian conference on diagnosis of dementia. Alzheimer Res Ther. 2013;5(Suppl 1):S2.","journal-title":"Alzheimer Res Ther"},{"issue":"3","key":"723_CR9","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jalz.2016.02.002","volume":"12","author":"B Dubois","year":"2016","unstructured":"Dubois B, Hample H, Feldman HH, Scheltens P, Aisen P, Andrieu S, et al. Preclinical Alzheimer\u2019s disease: definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016;12(3):292\u2013323.","journal-title":"Alzheimers Dement"},{"key":"723_CR10","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1098\/rsif.2011.0134","volume":"9","author":"CJ Thalhauser","year":"2012","unstructured":"Thalhauser CJ, Komarova NL. Alzheimer\u2019s disease: rapid and slow progression. J R Soc Interface. 2012;9:119\u201326.","journal-title":"J R Soc Interface"},{"key":"723_CR11","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.jalz.2017.02.006","volume":"13","author":"J Karlawish","year":"2017","unstructured":"Karlawish J, Jack CR Jr, Rocca WA, Snyder HM, Carrillo MC. Alzheimer\u2019s disease: the next frontier. Special report 2017. Alzheimers Dement. 2017;13:374\u201380.","journal-title":"Alzheimers Dement"},{"key":"723_CR12","unstructured":"Prince M, Wimo A, Guerchet M, Ali G-C, Wu Y-T, Prina M. World Alzheimer Report 2015. The global impact of dementia. An analysis of prevalence, incidence, cost and trends. London: Alzheimer\u2019s Disease International. 2015. https:\/\/www.alz.co.uk\/research\/world-report-2015. Accessed 14 Dec 2018."},{"key":"723_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2016.07.150","volume":"13","author":"A Wimo","year":"2017","unstructured":"Wimo A, Guerchet M, Ali GC, Wu YT, Prina AM, Winblad B, et al. The worldwide costs of dementia 2015 and comparisons with 2010. Alzheimers Dement. 2017;13:1\u20137.","journal-title":"Alzheimers Dement"},{"key":"723_CR14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2165\/11597380-000000000-00000","volume":"29","author":"J Shearer","year":"2012","unstructured":"Shearer J, Green C, Ritchie CW, Zajicek JP. Health state values for use in the economic evaluation of treatments for Alzheimer\u2019s disease. Drugs Aging. 2012;29:31\u201343.","journal-title":"Drugs Aging"},{"key":"723_CR15","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s40273-016-0389-9","volume":"34","author":"M Karimi","year":"2016","unstructured":"Karimi M, Brazier J. Health, health-related quality of life, and quality of life: what is the difference? Pharmacoeconomics. 2016;34:645\u20139.","journal-title":"Pharmacoeconomics."},{"key":"723_CR16","doi-asserted-by":"publisher","first-page":"336","DOI":"10.2165\/00019053-199610040-00004","volume":"10","author":"RT Anderson","year":"1996","unstructured":"Anderson RT, Aaronson NK, Bullinger M, McBee WL. A review of the progress towards developing health-related quality-of-life instruments for international clinical studies and outcomes research. Pharmacoeconomics. 1996;10:336\u201355.","journal-title":"Pharmacoeconomics"},{"key":"723_CR17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.tcmj.2012.09.002","volume":"5","author":"X-J Lin","year":"2013","unstructured":"Lin X-J, Lin IM, Fan S-Y. Methodological issues in measuring health-related quality of life. Tzu Chi Med J. 2013;5:8\u201312.","journal-title":"Tzu Chi Med J"},{"key":"723_CR18","doi-asserted-by":"crossref","unstructured":"Gallacher J, de Reydet de Vulpillieres F, Amzal B, Angehrn Z, Bexelius C, Bintener C, et al., and the ROADMAP Consortium. Challenges for optimizing real-world evidence in Alzheimer\u2019s disease: the ROADMAP project. J Alzheimers Dis 2019;67:495\u2013501.","DOI":"10.3233\/JAD-180370"},{"key":"723_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2008","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2008;6:e1000097.","journal-title":"PLoS Med"},{"key":"723_CR20","doi-asserted-by":"publisher","first-page":"e019082","DOI":"10.1136\/bmjopen-2017-019082","volume":"8","author":"F Landeiro","year":"2018","unstructured":"Landeiro F, Walsh K, Ghinai I, Mughal S, Nye E, Wace H, et al. Measuring quality of life of people with predementia and dementia and their caregivers: a systematic review protocol. BMJ Open. 2018;8:e019082.","journal-title":"BMJ Open"},{"key":"723_CR21","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jval.2017.09.005","volume":"21","author":"L Li","year":"2018","unstructured":"Li L, Nguyen KH, Comans T, Scuffham P, et al. Utility-based instruments for people with dementia: a systematic review and meta-regression analysis. Value Health. 2018;21:471\u201381.","journal-title":"Value Health"},{"key":"723_CR22","doi-asserted-by":"publisher","first-page":"d549","DOI":"10.1136\/bmj.d549","volume":"342","author":"RD Riley","year":"2011","unstructured":"Riley RD, Higgins JPT, Deeks JJ. Interpretation of random effects meta-analyses. BMJ. 2011;342:d549.","journal-title":"BMJ."},{"key":"723_CR23","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/rssa.12275","volume":"181","author":"K Rice","year":"2018","unstructured":"Rice K, Higgins JP, Lumley T. A re-evaluation of fixed effect(s) meta-analysis. J R Stat Soc A. 2018;181:205\u201327.","journal-title":"J R Stat Soc A"},{"key":"723_CR24","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jval.2010.08.002","volume":"14","author":"N Hounsome","year":"2011","unstructured":"Hounsome N, Orrell M, Edwards RT. EQ-5D as a quality of life measure in people with dementia and their carers: evidence and key issues. Value Health. 2011;14:390\u20139.","journal-title":"Value Health"},{"key":"723_CR25","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/01.wad.0000201851.52707.c9","volume":"20","author":"L J\u00f6nsson","year":"2006","unstructured":"J\u00f6nsson L, Andreasen N, Kilander L, Soininen H, Waldemar G, Nygaard H, et al. Patient- and proxy-reported utility in Alzheimer disease using the EuroQoL. Alzheimer Dis Assoc Disord. 2006;20:49\u201355.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"723_CR26","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s40258-016-0293-7","volume":"15","author":"J Ratcliffe","year":"2017","unstructured":"Ratcliffe J, Flint T, Easton T, Killington M, Cameron I, Davies O, et al. An empirical comparison of the EQ-5D-5L, DEMQOL-U and DEMQOL-Proxy-U in a post-hospitalisation population of frail older people living in residential aged care. Appl Health Econ Health Policy. 2017;15:399.","journal-title":"Appl Health Econ Health Policy"},{"key":"723_CR27","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1007\/s11136-017-1777-0","volume":"27","author":"T Easton","year":"2018","unstructured":"Easton T, Milte R, Crotty M, Ratcliffe J. An empirical comparison of the measurement properties of the EQ-5D-5L, DEMQOL-U and DEMQOL-Proxy-U for older people in residential care. Qual Life Res. 2018;27:1283\u201394.","journal-title":"Qual Life Res"},{"issue":"3","key":"723_CR28","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000076354","volume":"17","author":"A Vogel","year":"2004","unstructured":"Vogel A, Stokholm J, Gade A, Andersen BB, Hejl AM, Waldemar G. Awareness of deficits in mild cognitive impairment and Alzheimer\u2019s disease: do MCI patients have impaired insight? Dement Geriatr Cogn Disord. 2004;17(3):181\u20137.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"723_CR29","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/1471-2288-13-110","volume":"13","author":"AM Arons","year":"2013","unstructured":"Arons AM, Krabbe PF, Sch\u00f6lzel-Dorenbos CJ, van der Wilt GJ, Rikkert MGO. Quality of life in dementia: a study on proxy bias. BMC Med Res Methodol. 2013;13:110.","journal-title":"BMC Med Res Methodol"},{"key":"723_CR30","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1017\/S0033291713000494","volume":"44","author":"SA Vann Jones","year":"2013","unstructured":"Vann Jones SA, O'Brien JT. The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies. Psychol Med. 2013;44:673\u201383.","journal-title":"Psychol Med"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-020-00723-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13195-020-00723-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-020-00723-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T11:04:56Z","timestamp":1605697496000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-020-00723-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,18]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["723"],"URL":"https:\/\/doi.org\/10.1186\/s13195-020-00723-1","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,18]]},"assertion":[{"value":"16 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was not required because all work was carried out using previously published studies.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"YC is an employee of F. Hoffmann-La Roche Ltd. RH has received grants from ROADMAP (IMI2; public\u2013private collaboration; 2016\u20132019); consulting fees from Piramal, Roche and Eisai; and grants from Horizon 2020, JPND Joint Programming Neurodegenerative Disease Research, IMI Innovative Medicines Initiative, and national, European and patient charity funding organisations and private\u2013public collaborations (ZonMw Netherlands, Alzheimer Netherlands, Dutch Flutemetamol Study, Alzheimer Research UK, Swedish National study on Aging and Care, European Brain Council). PL is employed by, owns stock in and has stock options in Novartis Pharma AG. AG is a partner of Quantify Research, providing consultancy services to pharmaceutical companies and other private and public organisations and institutions. AG\u2019s contribution to ROADMAP was on behalf of Roche Pharmaceuticals. ERD is an employee of GE Healthcare. MB is an employee of and owns stock in Eli Lilly and Company Limited. GSJ is an employee of F. Hoffmann-La Roche Ltd. MHP is an employee of Biogen and owns stock in Biogen. She owns stock in a variety of companies that at times include other pharmaceutical and healthcare-related companies. ATH is an employee of and owns stock in Eli Lilly and Company Limited. FL, SM, KW, EN, JM, HW, IG, JL, NR, HW, JCB and AMG declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"154"}}